Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

8541. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients

Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients Brown R E, Hutton J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Docetaxel and paclitaxel chemotherapy in the management of advanced breast cancer patients. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population Patients with advanced breast cancer. Setting Oncology centres and the home. The economic study was conducted in the USA, Germany, Italy, the Netherlands, Spain and the UK. Dates to which data relate Effectiveness

NHS Economic Evaluation Database.1998

8542. Cost-utility assessment of amifostine as first-line therapy for ovarian cancer

Cost-utility assessment of amifostine as first-line therapy for ovarian cancer Cost-utility assessment of amifostine as first-line therapy for ovarian cancer Cost-utility assessment of amifostine as first-line therapy for ovarian cancer Bennett C L, Golub R M, Calhoun E A, Weinstein J, Fishman D, Lurain J, Roland P, Medio F, Bukowski R M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of amifostine as first-line therapy for ovarian cancer. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population A hypothetical population of 55 year old females with newly diagnosed, untreated ovarian cancer, with good performance status. Patients suffered from advanced ovarian cancer and received

NHS Economic Evaluation Database.1998

8543. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points

Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based (...) mitoxantrone and prednisone (M+P) was compared to prednisone alone (P) in patients with symptomatic hormone-resistant prostate cancer (HRPC). Type of intervention Palliative care. Economic study type Cost-utility analysis. Study population The study population comprised patients with symptomatic HRPC and pain. No further inclusion or exclusion criteria were reported. Setting The setting was tertiary care. The economic study was carried out in Canada. Dates to which data relate The dates during which

NHS Economic Evaluation Database.1998

8544. Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer: a European perspective

Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer: a European perspective Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer: a European perspective Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer: a European (...) perspective Berger K, Fischer T, Szucs T D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology First-line chemotherapy for patients with advanced ovarian cancer. Type of intervention Treatment. Economic study type Cost-effectiveness analysis

NHS Economic Evaluation Database.1998

8545. Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden

Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden Holmberg H, Carlsson P, Lofman O, Varenhorst E Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three-yearly prostate cancer screening for men aged 50-69 years. The screening involved digital rectal examination (DRE) by specialists and general practitioners (GPs) in the first screening round, DRE by GPs in the second round

NHS Economic Evaluation Database.1998

8546. Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer

Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer Hayman J A, Hillner B E, Harris J R, Weeks J C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Routine radiation therapy following conservative surgery for early-stage breast cancer. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population 60-year old women following conservative surgery. Setting Secondary care. The economic study was carried out in the United States

NHS Economic Evaluation Database.1998

8547. Cost-effectiveness in the management of patients with oesophageal cancer

Cost-effectiveness in the management of patients with oesophageal cancer Cost-effectiveness in the management of patients with oesophageal cancer Cost-effectiveness in the management of patients with oesophageal cancer Farndon M A, Wayman J, Clague M B, Griffin S M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology Treatments commonly used in the management of oesophageal cancer: surgical resection and palliative strategies. Type of intervention Treatment. Economic study type Cost-effectiveness analysis Study population Patients diagnosed with oesophageal cancer. Setting Secondary care. The economic analysis was carried out in Newcastle, United Kingdom. Dates to which data relate Effectiveness data were collected during

NHS Economic Evaluation Database.1998

8548. Faecal occult blood screening for colorectal cancer: is it cost-effective?

Faecal occult blood screening for colorectal cancer: is it cost-effective? Faecal occult blood screening for colorectal cancer: is it cost-effective? Faecal occult blood screening for colorectal cancer: is it cost-effective? Whynes D K, Neilson A R, Walker A R, Hardcastle J D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of the faecal occult blood (FOB) test for colorectal cancer (CRC) screening in an unselected population of men and women aged 50 to 74 years; those in the pilot study were aged 45 to 74 years. Type of intervention Screening. Economic study type Cost-utility analysis. Study population The study population comprised unselected men and women aged 50 to 74 years; the pilot study involved

NHS Economic Evaluation Database.1998

8549. Benefits of granulocyte-colony-stimulating factor after stem cell transfusion in intensive sequential chemotherapy for breast cancer

Benefits of granulocyte-colony-stimulating factor after stem cell transfusion in intensive sequential chemotherapy for breast cancer Benefits of granulocyte-colony-stimulating factor after stem cell transfusion in intensive sequential chemotherapy for breast cancer Benefits of granulocyte-colony-stimulating factor after stem cell transfusion in intensive sequential chemotherapy for breast cancer Viens P, Genre D, Protiere C, Gravis G, Bertucci F, Cowen D, Camerlo J, Chabannon C, Novakovitch G (...) intensive chemotherapy in patients with poor risk breast cancer. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Women who were at least 18 years of age and with histologically proven breast cancer with more than three involved homolateral axillary lymph nodes, a good Karnofsky performance status and normal haematologic, renal, hepatic and cardiac function. Setting Secondary care. The economic study was carried out in France. Dates to which data relate

NHS Economic Evaluation Database.1998

8550. The costs of treating breast cancer in the United Kingdom: implications for screening

The costs of treating breast cancer in the United Kingdom: implications for screening The costs of treating breast cancer in the United Kingdom: implications for screening The costs of treating breast cancer in the United Kingdom: implications for screening Wolstenholme J L, Smith S J, Whynes D K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening for breast cancer. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The treatment cost analysis was based on the case notes of 137 breast cancer patients. 102 patients had stage 1 cancer, 13 stage 2, 16 stage 3 and 6 had stage 4 cancer. This information was used to determine the screening scenario for the 2,687 new breast

NHS Economic Evaluation Database.1998

8551. Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluation

Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluation Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluation Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluation Messori A, Trippoli S, Becagli P, Tendi E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Treatments for newly diagnosed advanced ovarian cancer: (1) cisplatin-based chemotherapy at conventional doses without paclitaxel; (2) paclitaxel + cisplatin at conventional doses; and (3) high-dose chemotherapy with autologous hematopoietic rescue. Type of intervention Treatment. Economic

NHS Economic Evaluation Database.1998

8552. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis

What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prophylactic epoetin alfa as a potential alternative to reduce the blood transfusion requirements (caused by anaemia: blood haemoglobin less than 12g/dL) of patients receiving cancer chemotherapy. Type of intervention Secondary prevention. Economic study type Cost-benefit analysis. Study population The study population was based on cancer patients (half

NHS Economic Evaluation Database.1998

8553. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis

Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis Scott W J, Shepherd J, Gambhir S S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Use of thoracic positron emission tomography (PET) as an adjunct to thoracic CT for staging non-small cell lung cancer (NSCLC). Strategy A consisted of CT alone. The PET-based strategies considered were as follows: Strategy B implied that patients who were CT positive underwent a confirming biopsy, and if the biopsy results were negative, they proceeded to the necessary

NHS Economic Evaluation Database.1998

8554. Cost-effectiveness of detecting breast cancer in lower socioeconomic status African American and Hispanic women through mobile mammography services

Cost-effectiveness of detecting breast cancer in lower socioeconomic status African American and Hispanic women through mobile mammography services Cost-effectiveness of detecting breast cancer in lower socioeconomic status African American and Hispanic women through mobile mammography services Cost-effectiveness of detecting breast cancer in lower socioeconomic status African American and Hispanic women through mobile mammography services Schweitzer M E, French M T, Ullmann S G, McCoy C B (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A high-volume versus low-volume mobile mammography programme in the screening of indigent African American and Hispanic population for breast cancer. Type of intervention Screening

NHS Economic Evaluation Database.1998

8555. Cost analysis of transmural home care for terminal cancer patients

Cost analysis of transmural home care for terminal cancer patients Cost analysis of transmural home care for terminal cancer patients Cost analysis of transmural home care for terminal cancer patients Smeenk F W, Ament A J, van Haastregt J C, de Witte L P, Crebolder H F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology A transmural home care programme for terminal cancer patients. The programme intended to optimise communication, cooperation and coordination between the intra- and extra-mural health care organisations (transmural care). The transmural home care intervention programme was specifically aimed at assisting the primary care team, and consisted of four components: a specialist nurse co-ordinator, a 24 hour

NHS Economic Evaluation Database.1998

8556. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer

Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer Silber J H, Fridman M, Shpilsky A, Evens-Hoshan O, Smink D S, Jayaraman J, Fox K R, Pauly M V Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Granulocyte colony-stimulating factor (G-CSF) use in early-stage breast cancer. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with early-stage breast cancer. The population of patients was assumed

NHS Economic Evaluation Database.1998

8557. Review article: medical decision models of Helicobacter pylori therapy to prevent gastric cancer

Review article: medical decision models of Helicobacter pylori therapy to prevent gastric cancer Review article: medical decision models of Helicobacter pylori therapy to prevent gastric cancer Review article: medical decision models of Helicobacter pylori therapy to prevent gastric cancer Sonnenberg A, Inadomi J M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology H.pylori prevention and eradication programme in the prevention of gastric cancer. Type of intervention Primary prevention, screening, and treatment. Economic study type Cost-effectiveness analysis. Study population The US general population. Setting Hospital. This study was carried out in New Mexico, USA. Dates to which data relate Effectiveness data were

NHS Economic Evaluation Database.1998

8558. Endoscopic surveillance of Barretts esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer

Endoscopic surveillance of Barretts esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer Endoscopic surveillance of Barretts esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer Endoscopic surveillance of Barretts esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer Streitz J M, Ellis F H, Tilden R L, Erickson R V Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Endoscopic surveillance of Barrett's oesophagus to detect malignancy in an early and curable stage. Type of intervention Screening, diagnosis, and treatment. Economic study type Cost-effectiveness analysis. Study population Patients

NHS Economic Evaluation Database.1998

8559. Cost minimization analysis of high-dose-rate versus low-dose-rate brachytherapy in endometrial cancer

Cost minimization analysis of high-dose-rate versus low-dose-rate brachytherapy in endometrial cancer Cost minimization analysis of high-dose-rate versus low-dose-rate brachytherapy in endometrial cancer Cost minimization analysis of high-dose-rate versus low-dose-rate brachytherapy in endometrial cancer Pinilla J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using high-dose rate (HDR) versus low-dose rate (LDR) brachytherapy in the treatment of endometrial cancer. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Women with surgical stage 1 and 2 endometrial cancer who were undergoing adjuvant postoperative radiation. Setting Hospital. The economic study was carried

NHS Economic Evaluation Database.1998

8560. Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer

Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer Lind D S, Minter R, Steinbach B, Abbitt P, Lanier L, Haigh L, Vauthey J N, Russin M, Hackett R, Copeland E M Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Stereotactic core biopsy (SCB) in the diagnosis and management of patients with non-palpable breast cancer who underwent breast-conserving surgery. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population Patients

NHS Economic Evaluation Database.1998